Viyash Scientific Limited (VIYASH) — Announcement | 16 August 2026

Viyash Scientific reported robust Q1 FY27 results with 20% YoY revenue growth to Rs. 946 crores and 115% YoY PAT growth to Rs. 79 crores, driven by 59% EBITDA growth to Rs. 205 crores and net debt reduction to Rs. 86 crores (0.1x EBITDA). Management highlighted 23% constant currency growth in emerging markets, 60% domestic Animal Health growth, and 60% growth in US Human Formulations, while completing BioForLife acquisition integration. One-time ESOP expenses of Rs. 19 crores impacted PAT, but confidence remains high in sustaining 18-20% EU growth and expanding companion animal health revenue to 150-200 million by 2032 through strategic M&A and patent expiry-driven product launches post-2029.